Quantum Biopharma Class B Subordinate Voting Shares
QNTM
14 hedge funds and large institutions have $449K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
1,900% more call options, than puts
Call options by funds: $20K | Put options by funds: $1K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more funds holding
Funds holding: 13 → 14 (+1)
0.08% more ownership
Funds ownership: 1.16% → 1.24% (+0.08%)
18% less capital invested
Capital invested by funds: $549K → $449K (-$99.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$66.4K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$37.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$14.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.5K |
| 2 |
Jane Street
New York
|
-$20.7K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$18K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$13K |
| 5 |
HF
HRT Financial
New York
|
-$13K |
QNTM Hedge Fund Activity: Q4 2023 in Review
14 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q4 2023, worth a combined $449K — down 18% from $549K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new QNTM positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Scotia Capital, opening a new position worth an estimated $66.4K. The largest seller was Susquehanna International Group, cutting an estimated $56.5K.
- 14 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q4 2023, up from 13 in Q3 2023.
- Funds reported $449K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q4 2023, down 18% quarter-over-quarter.
- 5 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q4 2023 and 4 closed out, a net change of +1 holder.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q4 2023 was Scotia Capital, an estimated $66.4K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q4 2023 was Susquehanna International Group, an estimated $56.5K sold.
Based on aggregated 13F filings for Q4 2023.